EASL

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Database, DNA, Hou, EASL, Partnership, Therapy, NASH, Doctor of Philosophy, HBeAg, Janssen, CHB, MBA, RNA, HBsAg, Investment, SAN, Liver, R, ETV, Research, Pharmaceutical industry, Generic drug, Vaccine, Cryptocurrency, G&A

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.
  • “We continue to make important progress in advancing our portfolio of drug candidates,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • On July 31, 2023, Aligos Therapeutics, Inc. (the “Company”) and Janssen Biopharma, LLC (“Janssen”) filed a stipulation staying the case in their ongoing legal proceedings.
  • Cash, cash equivalents and investments totaled $90.8 million as of June 30, 2023, compared with $125.8 million as of December 31, 2022.

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, August 3, 2023
EASL, Arm, Drug development, Therapy, General counsel, Virology, NA, Clinical trial, Drug, Immunity, CTA, Viral, Roivant Sciences, Research, CFBV, RNA, Doctor of Philosophy, Arbutus, Congress, Medsafe, HBsAg, Investigational New Drug, Patent, MD, Patient, Investment, Immune system, Chief medical informatics officer, RNA interference, European Association for the Study of the Liver, PD-1, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, HBV, Food, Safety, Nivolumab, Pharmaceutical industry, Vaccine, Tutoring, Liver

We plan to provide a further update on this clinical trial when we have additional meaningful patient data.

Key Points: 
  • We plan to provide a further update on this clinical trial when we have additional meaningful patient data.
  • Preliminary data from patients in the clinical trial are expected in the second half of 2023.
  • The Phase 1 clinical trial with AB-161 is on-going with single-ascending dose data expected in the second half of 2023.
  • We expect to nominate an nsp12 inhibitor clinical candidate and initiate IND-enabling studies in the second half of 2023.

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, August 2, 2023
Intercept, Workforce, FXR, EASL, Bezafibrate, Therapy, NASH, Hepatology, Serum, PBC, Cholestasis, General Administration of Sport of China, Pharmacokinetics, Biomarker, Sale, Congress, Shanda, SAH, Patient, Intercept Pharmaceuticals, OCA, Mullard 5-10, Growth, Depreciation, Fatty liver disease, European Association for the Study of Diabetes, Research, FDA, Conference, Total, Safety, Pharmaceutical industry, Rare-earth element, Security (finance), Silviculture, Liver, FRESH, Obeticholic acid

Selling, general and administrative expenses increased to $53.3 million in the second quarter of 2023, from $40.0 million in the prior year quarter.

Key Points: 
  • Selling, general and administrative expenses increased to $53.3 million in the second quarter of 2023, from $40.0 million in the prior year quarter.
  • Research and development expenses decreased to $37.3 million in the second quarter of 2023, from $44.8 million in the prior year quarter.
  • In the second quarter 2023, Intercept reported a net loss from continuing operations of $5.8 million, a decrease compared to a net loss from continuing operations of $20.3 million in the second quarter 2022.
  • ET
    The conference call and webcast discussing the Company’s second quarter 2023 financial results will take place on August 2, 2023, at 8:30 a.m.

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes

Retrieved on: 
Thursday, July 27, 2023
World Hepatitis Alliance, WHA, EASL, Hepatitis, Life, HIV, Infection, World Hepatitis Day, Cancer, Hepatitis B, WHD, Liver cancer, CDA, Epidemic, C3, Death, Patient, Tuberculosis, Risk, Viral, Mortality, Viral hepatitis, Virus, HBV, HCV, Malaria, Vaccine

LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.

Key Points: 
  • LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.
  • The report finds that hepatitis B and C infected individuals "have a similar or significantly higher risk of developing cancer than someone who actively smokes one pack of cigarettes per day."
  • It concludes that HBV and HCV should be "considered as cancer causing infections and international guidelines should be reconsidered accordingly."
  • A recent survey2 from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral hepatitis.

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes

Retrieved on: 
Thursday, July 27, 2023
World Hepatitis Alliance, WHA, EASL, Hepatitis, Life, HIV, Infection, World Hepatitis Day, Cancer, Hepatitis B, WHD, Liver cancer, CDA, Epidemic, C3, Death, Patient, Tuberculosis, Risk, Viral, Mortality, Viral hepatitis, Virus, HBV, HCV, Malaria, Vaccine

LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.

Key Points: 
  • LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.
  • The report finds that hepatitis B and C infected individuals "have a similar or significantly higher risk of developing cancer than someone who actively smokes one pack of cigarettes per day."
  • It concludes that HBV and HCV should be "considered as cancer causing infections and international guidelines should be reconsidered accordingly."
  • A recent survey2 from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral hepatitis.

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

Retrieved on: 
Wednesday, July 12, 2023
EASL, Human, POC, Leibniz-Institute of Virology, Vaccination, CD3, CD28, Serum, HBeAg, University Medical Center, Institute of technology, Infection, Technical University of Munich, University Medical Center Hamburg-Eppendorf, Antibody, SCG, Hepatocyte, Liver cancer, Hepatitis B, HBsAg, Death, Cancer, Liver, Infant, CccDNA, Lymphocyte, HBV, Vaccine, Virology

A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.

Key Points: 
  • A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.
  • Levels of HBV pgRNA, HBV DNA, and cccDNA in the liver dropped significantly, consistent with the decrease of HBV serum parameters, indicating efficient clearance of infected hepatocytes.
  • One in three humans experiences an HBV infection during their lifetime, and almost 300 million people are chronically infected worldwide.
  • Approximately 25% of chronic HBV infections progress to liver cancer, and HBV contributes to an estimated 820,000 deaths annually.

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Retrieved on: 
Tuesday, July 11, 2023
SAB, EASL, Radiation, Society, European Society of Radiology, ZEUS robotic surgical system, ESR, Diagnosis, Editorial board, Woman, Abdominal Radiology, CIRSE, ILCA, Gastrointestinal tract, Interventional radiology, MD, Circulatory system, Executive Committee, Cardiovascular and Interventional Radiological Society of Europe, Health, Medical imaging, Radiology, Liver

Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.

Key Points: 
  • Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.
  • Dr. Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
  • “It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” commented Eyal Morag, MD, Chief Medical Officer.
  • She serves as reviewer of several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals.

1,000th alfapump® implant completed

Retrieved on: 
Thursday, July 6, 2023
Overload, EASL, Heart failure, Prevalence, Heart, Liver disease, Cancer, Quality of life, DSR, Patient, Brussels Stock Exchange, Ascites, Nashi, Cirrhosis, Medical imaging

The Company also reports that it has received all administrative clearances to start the US MOJAVE study of DSR 2.0 in congestive heart failure patients and expects to enroll the first patient imminently.

Key Points: 
  • The Company also reports that it has received all administrative clearances to start the US MOJAVE study of DSR 2.0 in congestive heart failure patients and expects to enroll the first patient imminently.
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “We developed the alfapump to transform the lives of patients with recurrent and refractory ascites due to liver disease.
  • A 63-year old alfapump patient from Canada said: “The alfapump changed my life.
  • I got lucky with the alfapump, my daily routine is getting back, with no pain and suffering, just feeling good

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

Retrieved on: 
Saturday, June 24, 2023
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, SEQUOIA, Arrowhead, EASL, Liver disease, Serum, The New England Journal of Medicine, TAK, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Trial of the century, Congress, Arrowhead Pharmaceuticals, Patient, European Association for the Study of the Liver, F4, Pharmaceutical industry, Takeda, Liver

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
  • The SEQUOIA Phase 2 data are consistent with the promising results from an open-label Phase 2 trial of fazirsiran (AROAAT2002) that were published in The New England Journal of Medicine .
  • Takeda (TSE:4502/NYSE:TAK) and Arrowhead are further investigating fazirsiran in the ongoing pivotal Phase 3 REDWOOD clinical study which is actively recruiting a total of 160 patients.
  • Fazirsiran treatment demonstrated a substantial effect on several key markers of liver disease,” said Javier San Martin, M.D., chief medical officer at Arrowhead.

Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

Retrieved on: 
Saturday, June 24, 2023
The New England Journal of Medicine, EASL, Nutrition, Histology, Tremor, University, FAST, NASH, Diarrhea, F2, NAS, Week, Vibration, Aes, Research, FGF21, Biomarker, Appetite, ELF, NEJM, Congress, Fibrosis, Clinical study design, Hepatitis, Vital signs, Patient, Metabolic syndrome, Nature, SAN, Division, Virginia Commonwealth University, Nausea, ALT, Fatty liver disease, DEXA, European Association for the Study of the Liver, FDA, Hepatology, Adiponectin, Cirrhosis, National Institutes of Technology (India), Safety, Biopsy, Pharmaceutical industry, Medical imaging, Liver, Gastroenterology, Glycated hemoglobin

SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH) were published online in the New England Journal of Medicine (NEJM). The data were simultaneously presented in a late-breaking oral session today at the European Association for the Study of the Liver (EASL) Congress 2023 in Vienna, Austria and were also selected for inclusion in the Best of EASL Congress summary.

Key Points: 
  • The published manuscript titled “A Randomized, Controlled Trial of the FGF21 Analog Pegozafermin in NASH” is available online.
  • A copy of the EASL oral presentation will be accessible under “Scientific Publications” in the pipeline section of 89bio’s website .
  • Treatment with pegozafermin also led to clinically meaningful changes compared to baseline in liver fat and other key non-invasive tests (NITs) of liver inflammation and fibrosis.
  • Five out of eleven of these patients treated with pegozafermin had fibrosis improvement ≥1 stage without worsening of NASH.